Mayne Pharma Group Ltd (ASX: MYX) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Mayne Pharma Group Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$206.36 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
81.25 million
Earnings per share
-1.043
Dividend per share
0.04
Year To Date Return
-20.26%
Earnings Yield
N/A
Franking
100%
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Mayne Pharma Group Ltd (ASX: MYX)
Latest News
Share Gainers
Why Allkem, Argosy Minerals, Mayne Pharma, and NextDC shares are racing higher
Earnings Results
Guess which ASX 300 share has rocketed 27% in 2 days since reporting
Share Gainers
Why De Grey, Kogan, Mayne Pharma, and Mesoblast shares are charging higher
Share Fallers
Why Gold Road, MA Financial, Mayne Pharma, and Westgold shares are dropping today
Share Market News
Why Arafura, Mayne Pharma, Pilbara Minerals, and Tyro shares are dropping today
Share Fallers
Why Coronado, IDP, Mayne Pharma, and Rio Tinto shares are dropping today
Share Fallers
Why Bubs, Collins Foods, Dusk, and Mayne Pharma shares are falling today
Share Fallers
Why is this ASX All Ords share crashing 27% today?
Share Gainers
Why Cogstate, Mayne Pharma, Race Oncology, and Whitehaven Coal are charging higher
Earnings Results
3 ASX healthcare shares punished following full-year results
Share Market News
3 ASX All Ordinaries shares rocking new 52-week highs on Wednesday
Healthcare Shares
Mayne Pharma share price rockets 25% on $680 million payday
Dividend Payment History Data provided by Morningstar.
| Ex-Date | Amount | Franking | Type | Payable |
|---|---|---|---|---|
| 18 Jan 2023 | $0.0272 | 100.00% | Special Cash | 27 Jan 2023 |
MYX ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Mayne Pharma Group Ltd
Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals It has a Forty-year track record of innovation and success in developing oral drug delivery systems. The Company's Business consists of three operating segments being International, Women's Health and Dermatology. The Dermatologysegment distributes dermatology products (branded and generic) in the U.S. on a portfolio basis, The Women's Health segment distributes branded women's health products in the U.S. International's segment revenue and gross profit are derived principally from the Australian manufacture and sale of branded and generic pharmaceutical products.
MYX Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 06 Mar 2026 | $2.54 | $0.06 | 2.42% | 397,068 | $2.50 | $2.55 | $2.44 |
| 05 Mar 2026 | $2.48 | $0.09 | 3.77% | 343,911 | $2.40 | $2.54 | $2.37 |
| 04 Mar 2026 | $2.39 | $-0.01 | -0.42% | 197,160 | $2.37 | $2.43 | $2.35 |
| 03 Mar 2026 | $2.40 | $-0.05 | -2.04% | 488,857 | $2.45 | $2.48 | $2.36 |
| 02 Mar 2026 | $2.45 | $-0.07 | -2.78% | 326,842 | $2.48 | $2.50 | $2.42 |
| 27 Feb 2026 | $2.52 | $-0.01 | -0.40% | 415,102 | $2.58 | $2.58 | $2.48 |
| 26 Feb 2026 | $2.53 | $-0.02 | -0.78% | 205,268 | $2.54 | $2.58 | $2.52 |
| 25 Feb 2026 | $2.55 | $0.01 | 0.39% | 262,106 | $2.53 | $2.60 | $2.53 |
| 24 Feb 2026 | $2.54 | $-0.07 | -2.68% | 355,765 | $2.61 | $2.64 | $2.50 |
| 23 Feb 2026 | $2.61 | $-0.04 | -1.51% | 1,296,768 | $2.64 | $2.66 | $2.60 |
| 20 Feb 2026 | $2.65 | $0.00 | 0.00% | 252,736 | $2.69 | $2.70 | $2.61 |
| 19 Feb 2026 | $2.65 | $0.01 | 0.38% | 233,763 | $2.66 | $2.67 | $2.62 |
| 18 Feb 2026 | $2.64 | $-0.01 | -0.38% | 222,547 | $2.65 | $2.70 | $2.62 |
| 17 Feb 2026 | $2.65 | $-0.06 | -2.21% | 227,821 | $2.72 | $2.72 | $2.62 |
| 16 Feb 2026 | $2.71 | $0.09 | 3.44% | 452,331 | $2.65 | $2.74 | $2.63 |
| 13 Feb 2026 | $2.62 | $-0.05 | -1.87% | 471,517 | $2.65 | $2.68 | $2.61 |
| 12 Feb 2026 | $2.67 | $-0.28 | -9.49% | 566,421 | $2.95 | $2.95 | $2.64 |
| 11 Feb 2026 | $2.95 | $0.11 | 3.87% | 796,524 | $2.92 | $3.04 | $2.85 |
| 10 Feb 2026 | $2.84 | $0.02 | 0.71% | 280,124 | $2.85 | $2.86 | $2.82 |
| 09 Feb 2026 | $2.82 | $0.19 | 7.22% | 431,768 | $2.70 | $2.85 | $2.68 |
| 06 Feb 2026 | $2.63 | $-0.07 | -2.59% | 398,605 | $2.68 | $2.76 | $2.60 |
| 05 Feb 2026 | $2.70 | $-0.03 | -1.10% | 267,622 | $2.73 | $2.75 | $2.69 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 18 Dec 2025 | Shawn O'Brien | Expiry | 72,821 | $220,647 |
As advised by the company. lapsed, 568193 Rights
|
| 18 Dec 2025 | Shawn O'Brien | Sell | 129,736 | $401,341 |
On-market trade.
|
| 18 Dec 2025 | Shawn O'Brien | Exercise | 326,452 | $989,149 |
Conversion of securities. 641014 rights
|
| 18 Dec 2025 | Shawn O'Brien | Buy | 326,452 | $989,149 |
Conversion of securities.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Professor Bruce Gregory Robinson AC | Non-Executive DirectorNon-Executive Chairman | Aug 2014 |
Prof Robinson is a Non-Executive Director of Cochlear Limited and CS Pharmaceuticals Limited. He is formerly a Board Member of the Woolcock Institute, was Chair of the National Health and Medical Research Council and Chair of the Medical Benefits Review Taskforce. Prof Robinson is Chair of the Science, Technology and Medical Committee.
|
| Ms Ann Custin | Non-Executive Director | Mar 2022 |
Ms Custin, a US resident, has almost 40 years of experience in the healthcare sector. Most recently, Ms Custin was Board Director and CFO of Siemens Medical Solutions (now Siemens Healthineers), a medical technology company with EUR20b in revenues. Previously, she was Chief Operating and Financial Officer of Scient'x Group and President and CEO of USA Draeger Medical Systems. Ms Custin is a Non-Executive Director of Establishment Labs Holdings Inc (NASDAQ:ESTA). Ms Custin is Chair of the Risk Committee.
|
| Dr Kathryn(Katie) MacFarlane | Non-Executive Director | Feb 2022 |
Dr MacFarlane, a US resident, has more than 30 years of experience in the pharmaceutical industry. She is currently Founder and Managing Partner of SmartPharma LLC, offering commercial and strategic consulting services to pharmaceutical companies. Previously, she was Chief Commercial Officer at Agile Therapeutics, Vice President Women's Health Care Marketing, Sales and New Product Planning at Warner Chilcott and Senior Director of Marketing at ParkeDavis (now Pfizer). Dr MacFarlane is a member of the of the Science, Technology and Medical Committee.
|
| Mr David Petrie | Non-Executive Director | Sep 2022 |
Mr Petrie is a M&A executive with over 30 years of advisory experience in public and private mergers and acquisitions, capital management and debt and equity raisings. He is currently Principal at Stratford Advisory Group, an independent corporate and financial advisory firm. Previously, he spent 23 years at Merrill Lynch/Bank of America including Managing Director and Head of Investment Banking Melbourne. He has worked on more than 100 transactions across a range of market sectors including healthcare. Mr Petrie is a member of the Risk Committee and the People Committee.
|
| Ms Laura Loftus | Company Secretary | Mar 2020 |
-
|
| Aaron Gray | Chief Financial Officer |
-
|
|
| Laura Loftus | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Citicorp Nominees Pty Limited | 19,388,698 | 23.86% |
| J P Morgan Nominees Australia Pty Limited | 7,192,510 | 8.85% |
| Mr Bruce Mathieson And Related Entities | 5,292,066 | 6.51% |
| HSBC Custody Nominees (Australia) Limited A/C 2 | 4,550,421 | 5.60% |
| HSBC Custody Nominees (Australia) Limited | 4,338,405 | 5.34% |
| BNP Paribas Noms Pty Ltd | 3,356,483 | 4.13% |
| BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient> | 2,283,879 | 2.81% |
| Solium Nominees (Aus) Pty Ltd <Unallocated A/C> | 2,045,519 | 2.52% |
| Bnp Paribas Noms Pty Ltd <Global Markets> | 1,499,974 | 1.85% |
| National Nominees Limited | 873,583 | 1.08% |
| Ecapital Nominees Pty Limited <Accumulation A/C> | 871,082 | 1.07% |
| Ivl Group Pty Ltd | 800,000 | 0.98% |
| Narlack Pty Ltd <Piperoglou Pension A/C> | 720,000 | 0.89% |
| BNP Paribas Nominees Pty Ltd <Agency Lending A/C> | 713,345 | 0.88% |
| Warbont Nominees Pty Ltd <Unpaid Entrepot A/C> | 524,893 | 0.65% |
| R & R Corbett Pty Ltd <R C Corbett Family A/C> | 522,028 | 0.64% |
| Bnp Paribas Nominees Pty Ltd <Cowen And Co Llc> | 500,000 | 0.62% |
| Neweconomy Com Au Nominees Pty Limited <900 Account> | 406,602 | 0.50% |
| Dr Kenney Wan | 360,020 | 0.44% |
| Akat Investments Pty Limited <Tag Family No2 Strategic A/C> | 330,000 | 0.41% |